Association between anxious depression and clinical outcomes in subjects with treatment-resistant depression: a comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment-resistant depression (ASCERTAIN-TRD)

International Clinical Psychopharmacology · Published 2026-05-13 · DOI 10.1097/yic.0000000000000628

Authors (23)

Stefania Chaikali, Clotilde Guidetti, Silvia Ioannou, Madhukar H. Trivedi, Richard C. Shelton, Dan V. Iosifescu, Michael E. Thase, Manish K. Jha, Sanjay J. Mathew, Charles DeBattista, Mehmet E. Dokucu, Olga Brawman-Mintzer, Glenn W. Currier, William Vaughn McCall, Matthew Macaluso, Alexander Bystritsky, Fidel Vila-Rodriguez, Erik B. Nelson, Albert S. Yeung, Leslie C. MacGregor, Thomas Carmody, Maurizio Fava, George I Papakostas

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Chaikali, S., Guidetti, C., Ioannou, S., et al. (2026). Association between anxious depression and clinical outcomes in subjects with treatment-resistant depression: a comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment-resistant depression (ASCERTAIN-TRD). International Clinical Psychopharmacology. https://doi.org/10.1097/yic.0000000000000628

Related articles

• Lumateperone monotherapy for major depressive episodes associated with bipolar disorder: efficacy and safety in a randomized placebo-controlled trial · International Clinical Psychopharmacology · 2025 · Same journal
• Unspoken needs: an essential perspective in the treatment of schizophrenia · International Clinical Psychopharmacology · 2026 · Same journal
• When antidepressants meet the gut microbiota: implications and challenges · International Clinical Psychopharmacology · 2024 · Same journal
• Innovations and challenges in antipsychotic treatments and external modulating factors · International Clinical Psychopharmacology · 2025 · Same journal
• Brexpiprazole augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary retrospective observational study · International Clinical Psychopharmacology · 2025 · Same journal
• The effects of lurasidone on five symptom domains and individual items in schizophrenia: Post-hoc analysis from Phase 3 study · International Clinical Psychopharmacology · 2025 · Same journal
• Risperidone as an adjuvant treatment for obsessive-compulsive symptoms in patients with bipolar disorder: a randomized, double-blind, placebo-controlled clinical trial · International Clinical Psychopharmacology · 2025 · Same journal
• Addressing the challenge of treatment adherence in major depressive disorder in different settings · International Clinical Psychopharmacology · 2026 · Same journal
• Efficacy and safety of adjunctive therapy with lumateperone in major depressive disorder: a randomized-, double-blind, placebo-controlled clinical trial · International Clinical Psychopharmacology · 2025 · Same journal
• Not all antipsychotic polypharmacy is the same · International Clinical Psychopharmacology · 2026 · Same journal